A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Summary

The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis \[JoAS\]) and juvenile psoriatic arthritis (JPsA).

Timeline

Start

2021-04-13

Primary completion

2024-02-19

Completion

2028-04

Publications

• Ramanan AV, Ruperto N, Foeldvari I, Vega-Cornejo G, Keller S, Wang R, Araujo J, Sen P, Marulkar K, Tseng J, Pitou C, Quartier P. Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab. Lancet Rheumatol. 2026 May;8(5):e377-e388. doi: 10.1016/S2665-9913(25)00346-7. Epub 2026 Mar 2.

Drugs

Indications